Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading

REFERENCES

• Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovas-cular disease. J Intern Med 1999; 246: 425–54.
   Google Scholar
• Hedner T, Himmelmann A, Hansson L. Homo-cysteine and ADMA—emerging risk factors for cardiovascular disease? Blood Press 2002; 11: 197–200.
   Google Scholar
• Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72: 315–23.
   PubMed Web of Science ®Google Scholar
• Boger RH, Bode-Boger SM. Asymmetric dimethy-larginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular dis-eases. Semin Thromb Hemost 2000; 26: 539–45.
   PubMedGoogle Scholar
• Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Jama 2002; 287: 1420–6.
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170–6.
   Google Scholar
• Cooke JP, Oka RK. Atherogenesis and the arginine hypothesis. Curr Atheroscler Rep 2001; 3: 252–9.
   Google Scholar
• Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-B6ger SM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99–105.
   Google Scholar
• Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asym-metric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholestero-lemia. Arterioscler Thromb Vasc Biol 2000; 20: 1557–64.
   PubMed Web of Science ®Google Scholar
• Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. Hyperhomocysteinemia after an oral methio-nine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848–52.
   Google Scholar
• Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998 9095; 351: 36 — 7.
   Google Scholar
• Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomo-cysteinemia: an effect reversible with vitamin C therapy. Circulation 1999; 99: 1156–60.
   Google Scholar
• Chambers JC, Obeid OA, Kooner JS. Physiologi-cal increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 1999; 19: 2922–7.
   Google Scholar
• Chao CL, Kuo TL, Lee YT. Effects of methio-nine-induced hyperhomocysteinemia on endothe-lium-dependent vasodilation and oxidative status in healthy adults. Circulation 2000; 101: 485–90.
   Google Scholar
• Chao CL, Lee YT. Impairment of cerebrovascular reactivity by methionine-induced hyperhomocys-teinemia and amelioration by quinapril treatment [In process citation]. Stroke 2000; 31: 2907–11.
   PubMed Web of Science ®Google Scholar
• Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999; 100: 1161–8.
   PubMed Web of Science ®Google Scholar
• Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocysteinaemia: restoration by folic acid. Chin Sci (Colch) 1999; 96: 235–9.
   PubMedGoogle Scholar
• Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, Giugliano D. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxi-dant vitamins. Jama 1999; 281: 2113–8.
   PubMed Web of Science ®Google Scholar
• Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dys-function during experimental hyperhomocystei-naemia in humans. Clin Sci (Lond) 2001; 100: 161–7.
   Google Scholar
• Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303: 131–7.
   Google Scholar
• Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994; 236: 633–41.
   Google Scholar
• Walker HA, McGing E, Fisher I, Boger RH, Bode-Boger SM, Jackson G, Ritter JM, Chowienczyk PJ. Endothelium-dependent vasodi-lation is independent of the plasma L-arginine/ ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001; 38: 499–505.
   Google Scholar
• Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842— 7.
   Google Scholar
• Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka O, Kokot F, Dubiel JS, Froelich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652–8.
   Google Scholar
• Paiva H, Laakso J, Laine H, Laaksonen R, Knuuti J, Raitakari OT. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 241–7.
   Google Scholar
• Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circu-lation 2002; 106: 987–92.
   Google Scholar
• Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001; 65: 775–8.
   Google Scholar
• Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001 9299; 358: 2127–8.
   Google Scholar
• Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104: 2569— 75.
   Google Scholar